Posts tagged CoLucid Pharmaceuticals
BTIG starts CoLucid Pharma at buy

BTIG initiated coverage of CoLucid Pharmaceuticals (NASDAQ:CLCD) with a “buy” rating and $58 price target, calling the company’s Lasmiditan drug candidate a game changer in acute migraine. The stock closed at $36.16 on Dec 21.

Read More